Removing the cytoplasmic domain may distract the immune response and instead generate antibodies that
target epitopes on Env that would not lead to protection.
Some targeted epitopes in the second variable (V2) loop of HIV Envelope, while others targeted glycans.
Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, Simmons G. Neutralizing monoclonal antibodies block Chikungunya virus entry and release by
targeting an epitope critical to viral pathogenesis.
Not exact matches
DPX - RSV is a small, B - cell
epitope peptide vaccine
targeting the unmet medical needs in respiratory syncytial virus (RSV).
Each
epitope is
targeted by a pool of T cells bearing different, but specific, T cell receptors to recognize and respond.
The
epitope where 2D22 binds to the virus may therefore represent a potential vaccine
target.
The
epitope defined by HMAb 2D22 is a potential
target for vaccines and therapeutics.
Post-infectious or post-vaccinal demyelinating encephalomyelitis and neuritis may be due to immunological cross-reactions evoked by specific viral antigenic determinants (
epitopes) that are homologous to regions in the
target myelins of the central and peripheral nervous systems.
Neutralizing antibodies primarily recognized the envelope protein domain III (EDIII) or quaternary
epitopes on the intact virus, and an EDIII -
targeted antibody protected mice against lethal infection.
In contrast, the tier 1 NAbs
targeted linear
epitopes in the gp120 V3 region.
In some cases, these NAbs
targeted components of the glycan shield previously associated with bNAb
epitopes.
Tier 2 NAbs recognized conformational
epitopes that differed between animals and in some cases overlapped with those recognized by broadly neutralizing antibodies (bNAbs), whereas tier 1 responses
targeted linear V3
epitopes.
epitope - a specific part on the surface of a virus that is
targeted for destruction by the body's immune system.
Epitope targeted might be preferentially expressed on HIV Env.
Epitope - tagged dopamine transporter knock - in mice reveal rapid endocytic trafficking and filopodia
targeting of the transporter in dopaminergic axons.
< i > In vivo performance of polymer nanocarriers dually -
targeted to
epitopes of the same or different receptors.
Investigation of Strategies for Drug Delivery by Combination
Targeting of Nanocarriers to Multiple
Epitopes or Receptors.
The high specificity with one
epitope target makes our monoclonal antibodies very efficient, reflecting in less background staining and low cross-reactivity with other proteins.
Emerging escape variants were generally resistant to the related V3 - specific antibody PGT121, but remained sensitive to antibodies
targeting nonoverlapping
epitopes, such as the anti-CD4-binding-site antibodies 3BNC117 and VRC01.
discovery of new vaccine
targets by innovative approaches that allow the identification of non-classical vaccine antigens like non-protein antigens and subdominant
epitopes and novel protein candidates
The overall score encompass several factors: reproducibility of the antibody staining in different cell lines (and if signal strength correlates with RNA expression levels); assays for enhanced antibody validation by using antibodies binding to different
epitopes on the same
target protein (independent antibodies), by knockdown / knockout of the
target protein (genetic methods) and by matching of the signal with a GFP - tagged protein (recombinant expression); experimental evidence for location described in literature.
If we think that the antibodies are keys that correspond to a lock
target located in the antigen, the
epitope would slot corresponding to a specific key.
Our immuno - oncology product candidates are being developed in two separate approaches: one that
targets specific antigens and / or
epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization (such as G100).
Epitopes are specific
target structures recognized by the immune system of human or animal body.
We predicted that these diversified
epitope regions would be the
targets of mutation as the 2009 H1N1 pandemic (pH1N1) lineage evolves in response to the development of population - level protective immunity in humans.
This approach is considered «passive,» as nanoparticles do not use ligands
targeting specific
epitopes on the cell surfaces.